Should You Buy Palantir Stock Before Dec. 13?

The Motley Fool
Updated
Mitrade
coverImg
Source: Shutterstock

Palantir Technologies (NASDAQ: PLTR) has had an incredible run in 2024. The company has become one of the most talked about platforms fueling the artificial intelligence (AI) narrative, shares of the stock have gained more than 300% this year alone, and it's become a member of the S&P 500 index.

But with just a few weeks left in the year, Palantir might have one last big milestone achievement up its sleeve. Below, I'm going to explain why Dec. 13 is an important date for Palantir investors. Let's break down what investors should be on the lookout for and assess if the stock is a good buy right now.

What is happening on Dec. 13?

This year, Dec. 13 falls on a Friday. And while Friday the 13th is usually affiliated with bad luck or superstition, Palantir investors may have some more good news headed their way.

Next Friday, the Nasdaq-100 index is going to be reconstituted. This means that a new selection of companies will be added to the coveted index, replacing stocks that have fallen out of eligibility.

This is important, because the Nasdaq-100 is generally affiliated growth stocks and lucrative opportunities beyond the S&P 500.

A humanoid robot looking at stock prices on an electronic display.

Image source: Getty Images.

Will Palantir join the Nasdaq-100?

On Sept. 6, Palantir announced that it had officially earned entry into the S&P 500. Since the date of that announcement, shares of Palantir have soared by 138% as of market close on Dec. 5.

A few months later, Palantir announced that it was changing the stock exchange on which it trades -- moving from the New York Stock Exchange (NYSE) to the Nasdaq.

PLTR Chart

PLTR data by YCharts

Since joining the Nasdaq on Nov. 26, shares of Palantir have gained about 10% (as of market close Dec. 5). That's a pretty dramatic move in only seven trading days.

In the press release regarding this announcement, management expressed that "upon transferring, Palantir anticipates meeting the eligibility requirements of the Nasdaq-100 Index."

While history is no guarantee of future results, the stock's performance following its entry into the S&P 500 and its transition to the Nasdaq serve as a decent proxy for what investors could expect should the company earn a spot on the Nasdaq-100 on Dec. 13.

Does joining the Nasdaq-100 make Palantir stock a buy?

I think there is a good chance Palantir will be added to the Nasdaq-100 next week and, should that occur, I'd be shocked if the stock doesn't move even higher. But while becoming a member of the Nasdaq-100 is a respectable milestone, such an achievement alone does not make Palantir stock a buy.

Instead, investors should look at a combination of the company's growth outlook, Wall Street's take on the company's trajectory, and valuation.

As far as Palantir's outlook and Wall Street's opinion are concerned, the company appears well on its way to continue accelerating its top line while growing margins and minting higher profits over the next several years.

The primary catalyst fueling this growth is Palantir's Artificial Intelligence Platform (AIP), which has become a game-changing product development for the company over the last couple of years. As such, some of Wall Street's most respected analysts including Dan Ives of Wedbush Securities and Mariana Pérez Mora of Bank of America remain bullish on the stock.

The only real concern I have surrounding an investment in Palantir at its current price comes down to valuation. To put it bluntly, a price-to-sales (P/S) multiple of 63.5 and a forward price-to-earnings (P/E) ratio of 149 are not even close to reasonable.

In my eyes, the stock has run up so much that it's due for a pullback sooner rather than later. But with that said, I see any potential sell-off as one that will be short-lived, as it will probably be driven by investors taking profits as opposed to panic-induced selling should Palantir face some sort of crisis -- which, as of now, doesn't look likely.

While the prospects of inclusion on the Nasdaq-100 is exciting, it's really just another potential milestone in what I see as a long line of more accomplishments to be achieved for Palantir over many years. All told, I'd encourage investors to monitor Palantir and look to use a strategy leveraging dollar-cost averaging over a long-term horizon.

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
AMD Reports Record Q4 Revenue, Shares Plunge 9% on Data Center MissAMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
Author  TradingKey
54 mins ago
AMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
placeholder
Microsoft Shares Slip on "Soft" Azure Revenue. Is This a Buying Opportunity in the Stock?Microsoft (NASDAQ: MSFT) shares fell after revenue from its Azure cloud computing platform came in at the low end of its prior guidance, although the unit continues to be company's
Author  The Motley Fool
Yesterday 03: 21
Microsoft (NASDAQ: MSFT) shares fell after revenue from its Azure cloud computing platform came in at the low end of its prior guidance, although the unit continues to be company's
placeholder
Novo Nordisk Q4 2024 Results: Will Wegovy Continue to Shine?TradingKey - One of the biggest trends in the healthcare space over the past few years has been the rise of so-called GLP-1 drugs.These can help treat type 2 diabetes and obesity but one of the other
Author  TradingKey
Yesterday 02: 41
TradingKey - One of the biggest trends in the healthcare space over the past few years has been the rise of so-called GLP-1 drugs.These can help treat type 2 diabetes and obesity but one of the other
placeholder
Where Will Nvidia Stock Be in 3 Years?If you held on to Nvidia (NASDAQ: NVDA) stock for the last three years, you are probably laughing all the way to the bank. A $10,000 bet made in early 2022 would be worth almost $5
Author  The Motley Fool
Feb 03, Mon
If you held on to Nvidia (NASDAQ: NVDA) stock for the last three years, you are probably laughing all the way to the bank. A $10,000 bet made in early 2022 would be worth almost $5
placeholder
ASML Crushes Q4 2024 Earnings: What are the Key Takeaways for Investors?In a big week for Big Tech earnings, semiconductor equipment giant ASML Holding NV (NASDAQ: ASML) reported its latest Q4 2024 earnings on Wednesday (29 January) before the market open in the US.ASML e
Author  TradingKey
Jan 31, Fri
In a big week for Big Tech earnings, semiconductor equipment giant ASML Holding NV (NASDAQ: ASML) reported its latest Q4 2024 earnings on Wednesday (29 January) before the market open in the US.ASML e